Izopet J
Laboratoire de virologie, centre national de référence virus des hépatites à transmission entérique (hépatites A et E), institut fédératif de biologie, CHU de Purpan, 330, avenue de Grande-Bretagne, TSA 40031, 31059 Toulouse, France; Inserm U1043/CNRS 5282, université Paul-Sabatier, centre de physiopathologie de Toulouse-Purpan, 31024 Toulouse cedex 03, France.
Ann Pharm Fr. 2018 Mar;76(2):89-96. doi: 10.1016/j.pharma.2017.12.007. Epub 2018 Feb 1.
HEV infections are mainly food- and water-borne but transfusion-transmission has occurred in both developing and developed countries. The infection is usually asymptomatic but it can lead to fulminant hepatitis in patients with underlying liver disease and pregnant women living in developing countries. It also causes chronic hepatitis E, with progressive fibrosis and cirrhosis, in approximately 60 % of immunocompromised patients infected with HEV genotype 3. Extra-hepatic manifestations such as neurological and renal manifestations have been reported. The risk of a transfusion-transmitted HEV infection is linked to the frequency of viremia in blood donors, the donor virus load and the volume of plasma in the final transfused blood component. Several developed countries have adopted measures to improve blood safety based on the epidemiology of HEV.
戊型肝炎病毒(HEV)感染主要通过食物和水传播,但在发展中国家和发达国家均有输血传播的病例。该感染通常无症状,但在发展中国家,潜在肝病患者和孕妇感染后可能会发展为暴发性肝炎。此外,约60%感染HEV 3型的免疫功能低下患者会出现慢性戊型肝炎,并伴有进行性纤维化和肝硬化。已有肝外表现的报道,如神经和肾脏表现。输血传播HEV感染的风险与献血者病毒血症的频率、供体病毒载量以及最终输注血液成分中的血浆量有关。一些发达国家已根据戊型肝炎的流行病学情况采取措施提高血液安全性。